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Disclosures
• BMJ Open Science (Editor-in-Chief)
– I receive an honorarium for this role
• I have applied and have received grant funding (& 
will continue) for this research
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My perspective
CAMARADES: Bringing evidence to translational medicine
Structure
• Scale of the problem
– How the life cycle of a preclinical research study is 
not fit for purpose
• In an ideal world
– As a consumer of preclinical research what do I 
want
• Potential solutions
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What is translational failure?
O’Collins et al, 2006
In vitro and in vivo - 1026
Tested in vivo - 603
Effective in vivo - 374
Tested in clinical trial - 97
Effective in clinical trial - 1
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Hypotheses
• In the life sciences there are perverse incentives 
(publication, funding, promotion) to produce 
positive results with little attention paid to their 
validity
• In the use of animal disease models, pressure to 
reduce the number of animals (cost, time, ethics, 
feasibility) results in studies either being 
underpowered or of unknown power
• These factors combine to compromise the utility of 
animal models and contribute to translational failure
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Translational failure
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What happens when pharma tries to 
replicate academic findings?
• Bayer, Berlin
• 67 in-house 
projects over 4 
years
Prinz et al, Nature Reviews 
Drug Discovery, 2011 
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Potential sources of bias in animal 
studies
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1.33 1.60 2.60 2.83 3.26
“Maze 
dull”
0.72 1.10 2.23 1.83 1.83
Δ +0.60 +0.50 +0.37 +1.00 +1.43
Rosenthal and Fode (1963), Behav Sci 8, 183-9
• 12 graduate psychology students
• 5 day experiment: rats in T maze with dark arm alternating 
at random, and the dark arm always reinforced
• 2 groups – “Maze Bright” and “Maze dull”
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Zubin Mehta 
Blind auditions explain ca. 30% of the increase in the female proportion of "new 
hires“ at major symphony orchestras in the US 
www.curt-rice.com




Conductor of the LA Symphony (1964-1978) and NY Philharmonic 
(1978-1990) credited with saying, “I just don’t think women 
should be in an orchestra.”
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Bias is prevalent and important
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The umbrella of reporting bias
Not all outcomes and a priori analyses are reported
• Publication bias
– Neutral and negative studies 
– Time lag/remain unpublished
– Less likely to be identified 
• p-hacking
– Selective analysis
– Selective outcome reporting
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• Overall efficacy was reduced from; 
– 32% (95% CI 30 to 34%) to 26% (95% CI 24 to 28%)
• 16% of experiments remain unpublished
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Ideally…………..
• Preclinical research will benefit from open science 
tools that facilitates:
– Clarity of how studies were performed 
• Robustness/replication
– Collaborative studies
• External validity 
– Confirmation that studies report what they set our to do
• Reporting biases
– Access to data that can be used and compared efficiently
• Robustness/replication
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Open Methods
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Study protocol registries
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Registered Reports
"Because the study is accepted in 
advance, the incentives for authors 
change from producing the most 
beautiful story to the most accurate 
one."
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Allow others to check your work
• Data should be available
• Undocumented data dumps
– No quality control
– Often not linked to original study
– How to re-analyse? 
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Publish data
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Who did what?
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THE open workflow
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How I do….
• My research has directly influenced my polices as an 
EiC
– Will publish sound science irrespective of results
– Encourage replication studies, preprints and protocol sharing
– Publish registered reports
– Use open peer review, open access
– Publish reviewing history
– Require open data & RRIDs
– TOP guidelines, FAIR data principles & OSF badges
– Use CRediT author contribution taxonomy, ORCiD
– Require ARRIVE but separately check Landis 4
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Benefits of open science
• For science
– Improved transparency of research that is more verifiable, 
efficient, reproducible and sustainable
• For society
– can readily gain access to, and use, scientific information
• For researchers
– More citations, more visibility, increased rigour and 
transparency of their work, better documentation
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Obstacles to researchers…..
• Limited
– Emphasis of rigour in grant award
– Emphasis of rigour in appointment panels
– CPD opportunities for scientists
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Effectiveness of research improvement
• Research Improvement Activity: Things done by 
stakeholders to increase the usefulness of research 
with which they are associated
• Important to assess whether interventions can be 
effectively delivered
• Important to assess whether interventions improve 
research quality and reduce waste
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RCT  - ARRIVE guidelines
• Control:
– 100% compliance  n=0 
manuscripts
– Median compliance 36.8% 
(29.7-42.1) of relevant 
items
• Intervention:
– 100% Compliance n= 0
– Median compliance 39.5% 
(31.6-44.7) of relevant 
items
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Key messages
• In vivo studies which do not report simple measures to avoid 
bias give larger estimates of treatment effects
• Most in vivo studies do not report simple measures to reduce 
bias
• Publication and selective outcome reporting biases are 
important and prevalent
• Intervention at reporting stage only is too late
• You can only find these things out by studying large numbers 
of studies
• Any experimental design can be subverted; what’s important 
is knowing how to recognise when this has happened
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Finally……
• Some (useful) tools exists
– I’m a little confused 
• Development/implementation needs resource 
• Research is required to determine their efficacy
• Education will help, including training in critical 
appraisal
• Reward/incentives will likely drive change
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Thanks to...........
